DMD #14860

Introduction
Flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-propanamide, Scheme 1) is a nonsteroidal antiandrogen drug that is widely used for the treatment of prostate cancer.
When used in combination with luteinizing hormone-releasing agonists or orchiectomy, flutamide has been shown to increase survival time of prostate cancer patients (Brogden and Clissold, 1989; McLeod 1993 , Schmitt et al. 2001 . However, the therapeutic effects of flutamide have been overshadowed by reports of temporary increases in transaminase markers and rare incidences of severe liver dysfunction (Wysowski and Fourscroy, 1996 , Osculati and Castiglioni, 2006 , Gomez et al., 1992 , Cetin et al., 1999 , Nakagawa et al., 1999 . Some cases have been associated with blood eosinophilia (Hart and Stricker, 1989) , which indicates an immune-mediated mechanism in some patients.
Investigations into the disposition of flutamide indicate that it is rapidly absorbed from the gastrointestinal tract in humans and rats (Schulz et al. 1988; Zuo et al. 2002; Katchen and Buxbaum 1975) . Maximum plasma concentrations up to 20 ng/mL have been attained in humans within 1 hr of oral administration of a single dose of 250 mg dose. However, administration of repeated 250 mg doses of flutamide resulted in the mean maximum plasma concentrations of 130 ng/mL. Flutamide undergoes extensive hepatic first-pass metabolism in humans and rats. The primary route of metabolism is the CYP1A2-mediated oxidation to 2-hydroxyflutamide although the formation of other oxidative metabolites and the involvement of CYP1A1 and CYP1B1 in the metabolism of flutamide have also been reported (Schulz et al. 1988 , Shet et al. 1997 , Watanabe et DMD #14860 al. 2001 Katchen and Buxbaum 1975) . 2-Hydroxyflutamide (M1, Scheme 1) appears to be largely responsible for the anti-androgenic activity of flutamide. In addition to oxidative metabolism, the esterase-catalyzed 4-nitro-3-(trifluoromethyl)phenylamine (FLU-1) metabolite has also been detected in human plasma (Schulz et al. 1988 
2006
; Goda et al. 2006) . Interestingly, reduction to a 4-amino derivative appears to be a minor pathway in the metabolism of flutamide in humans and preclinical species.
The mechanisms of flutamide-induced hepatotoxicity have not been precisely elucidated. Although nitro groups are generally implicated in various toxicities via reduction to an hydroxylamine or nitroso functionalities, studies with flutamide indicate that it is not detectably reduced by microsomal NADPH-cytochrome P450 reductase (Berson et al. 1993) . In contrast, oxidative bioactivation to a reactive metabolite is believed to be the cause of flutamide-induced toxicities. Studies by Berson et al. and Fau et al. suggest that flutamide undergoes a CYP3A4-and CYP1A2-catalyzed metabolism to reactive metabolite(s) that are covalently bound to hepatic proteins (Berson 1993 , Fau 1994 ). Ichimura and co-workers have also illustrated the necessity of enhanced flutamide metabolism for development of severe hepatotoxicity (Ichimura et al. 1999 ). More recently, Matsuzaki and co-workers have demonstrated the flutamide-induced toxicity after dosing flutamide to CYP1A2 knockout SV129 mice (Matsuzaki et al. 2006 ).
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Although several mechanistic studies have been performed to prove the involvement of metabolic activation in flutamide-induced hepatotoxicity, the nature of the reactive metabolite has yet to be identified. In vitro conjugation with GSH is a widely used method in the characterization of reactive metabolites and in probing the mechanism of bioactivation (Samuel et al 2003) . Recently, Soglia and co-workers have detected a GSH conjugate of hydroxylated flutamide in human liver microsomal incubations (Soglia et al. 2006) . Similarly, Tevell and co-workers (Tevell et al. 2006 ) have also detected a mercapturic acid conjugate of hydroxylated flutamide in the urine of prostate cancer patients. However, no definitive structural information of the conjugates or a proposed mechanism of bioactivation was presented in these reports. The present study was conducted to further probe the bioactivation of flutamide using GSH as a trapping agent and it has revealed the formation of a novel GSH conjugate in the incubations with human liver microsomes as well as heterologously expressed P450 isoforms. A tentative bioactivation mechanism was also proposed for the formation of this GSH conjugate.
Materials and Methods
Materials. Flutamide and reduced GSH were purchased from Sigma-Aldrich (St.
Louis, MO). Human liver microsomes were prepared from human livers (International Institute for the Advancement of Medicine, Jessup, PA) using standard protocols and were characterized using P450-specific marker substrate activities. Aliquots from the individual preparations from 56 individual human livers were pooled on the basis of equivalent protein concentrations to yield a representative microsomal pool with a protein concentration of 20.4 mg/ml. Recombinant P450 isozymes CYP1A2, 3A4, 2C8, 2C9, 2C19, and 2D6 supersomes were obtained from BD Gentest (Woburn, MA).
Respectively the protein concentration and P450 content of the recombinant enzymes were 4.5 mg/mL and 1 nmol/mL for CYP1A2; 7.6 mg/mL and 1 nmol/mL for CYP3A4; 4.9 mg/mL and 2 nmol/mL for CYP3A5; 3.2 mg/mL and 1 nmol/mL for CYP2C8; 2.6 mg/mL and 2 nmol/mL for CYP2C9; 6.9 mg/mL and 1 nmol/mL for CYP2C19; 8.3 mg/mL and 1 nmol/mL for CYP2D6. All other commercially available reagents and solvents were of either analytical or HPLC grade.
Incubation of flutamide with human liver microsomes. Flutamide (5 µM to 100 µM) was incubated for 1 h at 37 °C in an incubation system consisting of 100 mM potassium phosphate buffer (pH 7.4), 2 mg human liver microsomes and 5 mM GSH in a final volume of 1 mL. After 3 min preincubation, incubations were initiated by the addition of DMD #14860 residues were reconstituted in 200 µL of 30:70 (v/v) methanol:20 mM ammonium acetate (pH 4) and aliquots (100 µL) were injected into an HPLC-MS system.
Metabolite profiling was performed on an Agilent 1100 HPLC system (Wilmington, DE) coupled with a Finnigan LCQ-Deca ion-trap mass spectrometer (San Jose, CA).
Separation was achieved using a kromasil C4 100A column (3.5 µm, 150 x 2.0 mm, Phenomenex, Torrance, CA) at a flow rate of 0.2 mL/min. A gradient of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % formic acid was as follows: initiated with 1 % B for 5 min and then increased in a linear manner to 30% at 20 min and to 50% at 25 min, held at 50% until 28 min, changed linearly to 90% at 40 min, maintained at 90% for up to 43 min and then decreased to 1% at 45 min. The column was allowed to equilibrate at 1% solvent B for 5 min prior to the next injection. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the The adduct was separated by a kromasil C4 100A column (3.5 mm, 150 x 2.0 mm, Phenomenex, Torrance, CA) at a flow rate of 0.2 mL/min. A gradient of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % formic acid was as follows: initiated with 0% B for 3 min and then increased in a linear manner to 90% at 15 min and then decreased to 0% at 17 min. The column was allowed to equilibrate at 0% solvent B for 3 min prior to the next injection. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 3 min after sample injection.
The Q-trap 4000 ESI-MS was operated in the negative ionization mode, by applying to the capillary a voltage (IS) of -4.5 kV. Nitrogen was used as curtain gas (CUR), as well as nebulizing (GS1) and turbo spray gas (GS2, heated at 450 °C), with the optimum values set, respectively, at 36, 50, and 40 (arbitrary values). Collisionally activated dissociation (CAD) was performed at 6 (arbitrary value) with nitrogen as the collision gas. Declustering potential (DP) was set at -90 V, whereas entrance potential (EP) was set at -10 V; collision energy (CE) was optimized at -34 eV. The MRM transitions used were 580→307 for the glutathionyl adduct M2 and 316→205 for internal standard nilutamide, respectively. The amounts of M7 produced by CYPs were represented by the ratio of peak areas of M7 to that of internal standard, nilutamide. The CYP-mediated formation of M7 was normalized to CYP2C19.
Isolation of GSH Adduct and NMR Characterization.
Rat liver microsomes were used to scale up the formation and isolation of the GSH conjugate. The incubation with flutamide was carried out in a final volume of 10 mL. The incubation conditions were similar to those described above. The corresponding GSH conjugate was isolated with the LC conditions as follows. Separation was achieved using a COSMOSIL 5PYE column (150 x 4.6 mm, Waters, Milford, MA) at a flow rate of 1.0 mL/min with an Agilent 1100 HPLC system (Wilmington, DE). A gradient of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % formic acid was as follows: initiated with 100% A for 5 min, changed to 80% A from 5 to 10 min, changed to 50% A from 10 to 60 min, change to 10% A from 60 to 70 min, held at 10% A from 70 to 75 min, changed to 100% A from 75 to 76 min, and held at 100% A from 76 to 80 min for the column to be equilibrated.
Approximately 6 µ g of the material was isolated from the incubation mixture. All NMR spectra were acquired on a Bruker-Biospin AV700 spectrometer running TopSpin 1.3 software and equipped with a Bruker 5-mm TCI z-gradient Cryoprobe (Bruker, Rheinstetten, Germany).
1
H NMR spectra were acquired with water suppression using a Watergate W5 pulse sequence with gradients and a double echo. 2D COSY and HSQC spectra were acquired without solvent suppression using gradient pulses for coherence selection. Chemical shifts are reported in ppm relative to tetramethylsilane. Figure 3B . This mass spectral data suggested that the GSH moiety was conjugated to the flutamide molecule via the amide nitrogen, resulting in a sulfenamide, and not on the aromatic ring or the isopropyl group of flutamide.
The proposed structure of M7 was further confirmed by NMR experiments to obtain more definitive structural information on the GSH conjugate. Since M7 was formed in larger amounts in rat liver microsomal incubations with flutamide (data not shown), rat liver microsomes were used to produce sufficient amounts of M7 for NMR experiments.
This article has not been copyedited and formatted. The final version may differ from this version. phenacetin via N-hydroxy-p-phenetidine, and GSH (Mulder et al. 1984; Gallemann et al 1998) . However, the formation of N-acylsulfenamide, similar to the one described in this report, is not known. In the present study, the conjugate M7 was stable enough to be isolated and characterized by NMR. This was consistent with literature reports which have indicated modest stability of N-GSH conjugates in water (Mulder et al. 1984) .
Since previous studies have reported the oxidative bioactivation of flutamide to chemically reactive intermediates, all incubations in this study were performed under aerobic conditions. The NADPH-dependent GSH conjugate formation indicated that one or more P450s were involved in the production of the reactive intermediate by
human liver microsomes. Experiments with bacculovirus-expressed recombinant P450
This article has not been copyedited and formatted. The final version may differ from this version. enzymes revealed that both P450 2C19 and 1A2 were involved in the formation of M7
when GSH was present in the incubation mixtures. CYP 3A4 and 3A5 were also able to catalyze the oxidation of flutamide to yield M7, but to a lesser degree. The CYP1A2
and 3A4-mediated formation of M7 was consistent with the previous reports that suggested involvement of these two enzymes in the bioactivation of flutamide (Berson et al. 1993; Matsuzaki et al 2006) . Recent reports on metabolism of flutamide to hydroxyflutamide (M1) have demonstrated the involvement of CYP2C19 in its formation (Goda et al., 2006) ; however, the involvement of 2C19 in the bioactivation of flutamide has not been previously reported. The mechanism for formation of M7 is unknown at this time. However, several mechanisms that result in conjugation of GSH and flutamide can be speculated.
Reports was not detected in incubations of flutamide with human liver microsomes in our study.
Although speculative, one pathway for the formation of M7 could involve the combination of radical 1 with the thiolate anion of GSH (that is in equilibrium with GSH)
to give the corresponding thiolate anion radical 3 which is then oxidized to M7 (pathway A, Scheme 2). Thiolate anion radicals have been previously proposed as intermediates during formation of GSH disulfide (GSSG) (Buettner, 1993) . Alternatively, 1 could recombine with GSH radical to yield M7 (pathway B, Scheme 2). Interestingly, does not prove the mechanism for the formation of M7 it suggested that pathway B illustrated in Scheme 2 could be one of the ways to form M7. Previous reports have shown a decrease in the GSH and thiol content and an increase in the GSSG/GSH ratio following incubation of flutamide with isolated rat hepatocytes (Fau D 1994) . It is possible that the reaction is mediated by the nitrogen-centered radical proposed in this study which can oxidize GSH or thiol containing proteins.
Microsomal incubation of flutamide in the presence of GSH and NADPH also resulted in the formation of G1, a deglutamyl derivative of M7. It is known that GSH conjugates formed in vivo undergo γ-glutamyl-transpeptidase catalyzed hydrolysis to form adducts similar to G1 (Horvath, 1992; Meister and Tate, 1980, Horiuchi et al. 1978) . However, such hydrolytic cleavages are rarely observed within in vitro microsomal incubations.
Since this was a minor metabolite in the incubation mixture, no attempt was made to further characterize G1 in this study.
In summary, a novel GSH conjugate of flutamide was identified and characterized in this study. Although the relevance of this pathway in flutamide-induced toxicity is not known, the P450-mediated formation of this conjugate suggests that the proposed radical formation could possibly be one of the several bioactivation pathways by which flutamide induces its hepatotoxicity.
This article has not been copyedited and formatted. The final version may differ from this version. The insert is the expanded region of the aromatic group. The spectrum was obtained by dissolving the isolated M7 in deuterated methanol. represented by the ratio of peak areas of M7 to that of internal standard, nilutamide. The CYP-mediated formation of M7 was normalized to CYP2C19. This article has not been copyedited and formatted. The final version may differ from this version.
